News
Seminar Series
February 24, 2008 |
Dr. Theodore D. Moustakas Dr. Lee E Goldstein Host Program: Boston University Photonics Center |
| Abstract: Dr. Theodore D. Moustakas The GaN R&D effort at Boston University addresses both fundamental issues as well as device applications. The fundamental issues include the epitaxial growth of the entire family of III-Nitride Semiconductors, the development of probes for monitoring the growth in-situ, the study of the crystal structure, the theoretical and experimental investigation of the electronic structure and defects. The device applications include emitters and detectors in the UV, LEDs and lasers in the visible, as well as infrared and terahertz emitters based on intersubband transitions in AlGaN Multiple Quantum Wells (MQWs) In this talk I will briefly review the various activities of the program and focus particularly on our research related to LEDs for solid state lighting and various applications in the UV. Such devices are based on InGaN or AlGaN Multiple Quantum Wells (MQWs) or Quantum Dots (QDs). The current emphasis of the program is to develop such devices using textured QWs grown on non-polar GaN templates. The physics and benefits of using textured MQWs in LED structures based on these polar materials will be addressed. This approach leads to an increase in internal quantum efficiency by suppressing the polarization degrading effects and an increase in extraction efficiency due to textured external surface. Dr. Lee E Goldstein Alzheimer’s disease (AD) is a leading contributor to mortality, morbidity, and healthcare costs. Although hundreds of emerging AD therapeutics aimed at the underlying disease show great promise, effective treatment will remain elusive unless coupled with early (pre-symptomatic) disease detection. Development of new diagnostic technology for screening and early detection is now an urgent national research priority. Based on our discovery of AD-linked beta-amyloid (Aß) pathology in the lens of the eye (Goldstein et al., Lancet, 2003), we are now developing innovative non-invasive bio-optical laser technology for quantitative molecular diagnostic detection of AD from the very earliest stages of the disease, before onset of cognitive symptoms and irreparable damage to the brain. A new paradigm linking early molecular detection with early therapeutic intervention holds near-term promise for effective treatment for this devastating disease. |
|
